Celgene (CELG): Clinical CELMoD Data Creates LT Optionality - BMO

September 30, 2016 7:46 AM EDT
Get Alerts CELG Hot Sheet
Price: $112.66 -4.03%

Rating Summary:
    28 Buy, 8 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 31 | New: 25
Trade CELG Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

BMO Capital analyst, Ian Somaiya, reiterated his Outperform rating on Celgene (NASDAQ: CELG) after the company unveiled clinical data from its CELMoD pipeline, showcasing its expertise in protein homeostasis.

The near-term impact on CELG shares is expected to be limited but the pipeline optionality from 2020-30 could be meaningful. Promising early clinical results from ongoing trials of CC-122 in DLBCL and CC-220 in Lupus highlighted the company’s knowledge of Cereblon and the use of biomarker and PD data to drive efficacy.

The analyst believes CC-220 could be ideally suited for myeloma but the drug’s success in an ongoing lupus trial could also lead to Celgene pursuing a back-up compound.

No change to the price target of $141.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $102.77 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

BMO Capital

Add Your Comment